Vertex CF drug Kalydeco wins Aussie nod; GSK's Votrient gains full approval in EU;

@FiercePharma: Pfizer's vaccine hope Prevenar 13 wins new EU nod in adults. Will it translate into big sales? Report | Follow @FiercePharma

 @EricPFierce: Hikma ups doxycycline capacity as it brings production back at NJ plant that got FDA warning letter. ICYMI | Follow @EricPFierce

 @CarlyHFierce: Investors unhappy with plans from Russia's Pharmstandard to spin off OTC biz. May also buy Singapore-based Bever. Yesterday's story | Follow @CarlyHFierce

> Vertex Pharmaceuticals ($VRTX) won Australian approval for Kalydeco, its targeted drug for cystic fibrosis patients. Report

> GlaxoSmithKline's ($GSK) cancer drug Votrient saw its conditional approval status lifted in Europe, gaining full approval for marketing there. Release

> Prestige Brands, a maker of house-brand over-the-counter drugs, bought Australia's Care Pharmaceuticals to expand in the Asia-Pacific region. Report

> India's pharmaceutical exports are still growing, but at half the rate of two years ago, thanks to slowdowns in North America and Europe. Report

> A plaintiff's lawyer is pushing the FDA to release data on Johnson & Johnson's ($JNJ) antipsychotic drug Risperdal, the subject of a liabiity case that he is pursuing, to get around a judge's seal on the documents. Report

> Animal health company Dechra posted a 19% hike in fiscal year revenue but expects the current year to be a challenge. Report

> Sun Pharmaceuticals stock enjoyed a boost from good news about a competitor's strong sales of a generic antibiotic Sun also sells. Report

Medical Device News

@FierceMedDev: Myriad sues Ambry over Dx gene patents. News | Follow @FierceMedDev

 @MarkHFierce: Are CT scans overused in children? A new study concludes that they are, boosting cancer risks. ICYMI yesterday | Follow @MarkHFierce

@DamianFierce: NeuroPace has hauled in another $18M to get its anti-epilepsy implant through the FDA process. Story | Follow @DamianFierce

> Blockbusters and bloodlettings: A look at 2013's hot M&A start. Special report

> Abbott rides next-gen Xience stent into Japan. Article

> Diaper device designed to flag babies' health problems. More

Biotech News

@FierceBiotech: ChemAxon extends pharma software streak with Schrödinger deal. Article | Follow @FierceBiotech

 @JohnCFierce: When does pursuing a clinical study become unethical? Roche needs to review that question in the wake of aleglitazar fiasco. More | Follow @JohnCFierce

@RyanMFierce: Over 7 years EU & industry pumping €22.6B into R&D, €4.8B in pharma, to spur economic activity. Is it enough? Release | Follow @RyanMFierce

 @EmilyMFierce: 5 lessons from @FierceBiotech's rebooted LinkedIn group. Editor's corner | Follow @EmilyMFierce

> 'Breakthrough' ibrutinib NDA makes rapid arrival at FDA. News

> Biotech billionaire Kirk reaches for $125M score in Intrexon IPO. Story

Biomarkers News

> Urine-based genetic test triumphs in trial. More

> Measuring electrical frequencies in brain could indicate Huntington's disease. Report

> U.K. Dx zeroes in on bladder cancer biomarkers in urine odor. Story

> Measuring electrical frequencies in brain could indicate Huntington's disease. Article

> Biomarker could guide decision on follow-up breast cancer treatment. News

Drug Delivery News

> Acorda grabs liquid and patch pain treatments for $8M-plus. Article

> BDSI hauls in $20M for pain film, addiction gel. More

> Oramed launches oral insulin safety trial. Report

> European injectable drug delivery market poised to soar. News

> Antibiotic-delivery strategies could cut back on side effects. Story

And Finally... A Cornell University scientist is on a crusade to develop the perfect broccoli. Report

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.